Abstract:Objective To evaluate the clinical significance of 24 antiphospholipid antibodies in pregnant women with antiphospholipid syndrome(APS). Methods Case-control study was carried out: 28 APS pregnant women, 34 non-APS pregnant women and 39 health controls were enrolled. Anti-cardiolipin (aCL), anti-β2-glycoprotein 1(aβ2GP1), anti-annexin-A5 anti-prothrombin antibodies (aPT), anti- phosphatidylserine antibodies aPS, anti-phosphatidyl ethanolamine antibodies (aPE), anti-phosphatidyl inositol antibodies (aPI), anti-phosphatidyl choline antibodies (aPC), anti-sphingomyelin antibodies (aSPH), antibodies (aAXN5), and anti-phosphatidylserine-prothrombin complex antibodies (aPT/PS) were detected by enzyme-linked immununosorbent assay(ELISA). Lupus anticoagulant (LA) was tested by Dilute Russell′s viper venom time (dRVVT). The prevalence of antiphospholipid antibodies in the three groups were compared (Chi-Square test or Fisher′s exact test). The antibody levels in different groups were compared using nonparametric Mann–Whitney U tests. The diagnostic efficacy of antiphospholipid antibodies was analyzed by cross table using clinical diagnosis of APS as gold standard. Results The prevalence of aCL-IgM, aβ2GP1-IgG, aβ2GP1-IgA, aPT/PS-IgG, aPT/PS-IgM, aPS-IgG, aPI-IgG,and LA were higher in APS pregnant women than those in non-APS pregnant women (P 97.1%) in differentiating APS pregnant women from non-APS in pregnant women. Although there was no significantly differenct prevalence of aPLs between patients with thrombosis and without thrombosis, the median levels of aCL-IgM [19.3(43.2) MPL/ml vs 8.3(17.7) MPL/ml], aPT/PS-IgG [71.4(78.2) U/ml vs 16.7(31.5) U/ml], aPT/PS-IgM [95.0(127.7) U/ml vs 15.3(15.1) U/ml], aPT-IgG [9.1(18.1) U/ml vs 5.0(4.1) U/ml] and LA [1.70(0.29) vs 1.21(0.41)] were significantly higher in patients with thrombosis (P=0.006, P=0.041, P=0.019, P=0.041, and P=0.006, respectively). Furthermore, the prevalence of multiple aPLs was significantly higher in APS pregnant women with thrombosis than those without thrombosis (86.67% vs. 38.46%, P=0.016). Conclusions LA, aCL-IgM and aPI-IgG play important roles in diagnosising APS in pregnant women. More antiphospholipid antibodies could be found in patients with thrombosis than those without thrombosis, and the levels of these antibodies are higher in the patients with thrombosis than in the without thrombosis. Key words: Antiphospho1ipid syndrome; Pregnancy complications; Antiphospholipid antibodies

Risk Factors for Adverse Pregnancy Outcomes in Patients with Antiphospholipid Syndrome

Risk factors for adverse pregnancy outcomes in obstetric antiphospholipid syndrome

Risk Factors for Pregnancy Morbidity in Women with Antiphospholipid Syndrome.

Research Progress on the Relationship between Anticardiolipin Antibodies and Adverse Pregnancy Outcomes

Clinical Features Associated with Pregnancy Outcomes in Women with Positive Antiphospholipid Antibodies and Previous Adverse Pregnancy Outcomes: a Real-World Prospective Study.

Pregnancy Outcome in 54 Patients with Antiphospholipid Syndrome: a Retrospective Clinical Study

68 Identifying Clinical and Epidemiological Risk Factors Associated with Thrombosis and Pregnancy Morbidity in a Large Cohort of Chinese Aps Patients

High-risk factors for adverse pregnancy outcomes in systemic lupus erythaematosus: a retrospective study of a Chinese population

Biochemical and clinical predictors in pregnant women with antiphospholipid syndrome and systemic lupus erythematosus: comprehensive update

Hemorrhage complications in obstetric antiphospholipid syndrome: Risk factors and association with adverse pregnancy outcomes

Impact of Antiphospholipid Syndrome on Reproductive Outcomes: Current Insights and Management Approaches

Risk factors associated with adverse pregnancy outcomes in patients with new-onset systemic lupus erythematosus during pregnancy

Additional risk factors associated with thrombosis and pregnancy morbidity in a unique cohort of antiphospholipid antibody-positive patients

Cluster Analysis of Antiphospholipid Antibodies-Associated Adverse Pregnancy Outcome Patients: Based on a 13-Years Cohort Study.

Risk factors for pregnancy failure in patients with antiphospholipid antibody positivity and prior pregnancy losses: A retrospective study

Risk Factors for Adverse Pregnancy Outcomes in Women with Rheumatoid Arthritis and Follow-Up of Their Offspring

[Pregnancy and antiphospholipid syndrome]

Perinatal outcomes in indian women with Antiphospholipid Antibody Syndrome (APS): Five year experience from a tertiary care centre

Clinical Significance of Antiphospholipid Antibodies in Pregnant Women with Antiphospholipid Syndrome

Fetal outcomes and associated factors of adverse outcomes of pregnancy in southern Chinese women with systemic lupus erythematosus

The impact of various entities of antiphospholipid antibodies positivity on adverse pregnancy outcome. An epidemiological perspective